CIK 0001739410 · <br>Emerging growth company
Rallybio Corp
Sign in to watch- Ticker
- RLYB
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 851083789
- Phone
- 203- 859-3820
- Business address
- 234 CHURCH STREET, SUITE 1020, NEW HAVEN, CT, 06510
- Former names
- Rallybio Holdings, LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $9,608
- in 1 filing
Net −$9,608. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-02-14 | Lieber Jonathan I Chief Financial Officer | Grant or award · Option (Right to Buy) | +180,000 | 180,000 | ||
| 2025-01-02 | MACKAY MARTIN Director | Grant or award · Option (Right to Buy) | +92,857 | $0.70 | $65K | 92,857 |
| 2025-01-02 | HUNT RONALD Director | Grant or award · Option (Right to Buy) | +73,571 | $0.70 | $51K | 73,571 |
| 2025-01-02 | Hopfner Robert Lorne Director | Grant or award · Option (Right to Buy) | +73,571 | $0.70 | $51K | 73,571 |
| 2025-01-02 | Liu Hui Director | Grant or award · Option (Right to Buy) | +67,857 | $0.70 | $47K | 67,857 |
| 2024-05-15 | HUNT RONALD Director | Grant or award · Option (Right to Buy) | +16,500 | 16,500 | ||
| 2024-05-15 | Boudreau Helen M Director | Grant or award · Option (Right to Buy) | +16,500 | 16,500 | ||
| 2024-05-15 | Liu Hui Director | Grant or award · Option (Right to Buy) | +16,500 | 16,500 | ||
| 2024-05-15 | PARMAR KUSH Director | Grant or award · Option (Right to Buy) | +16,500 | 16,500 | ||
| 2024-05-15 | Soteropoulos Paula Director | Grant or award · Option (Right to Buy) | +16,500 | 16,500 | ||
| 2024-05-15 | Nash Christine A Director | Grant or award · Option (Right to Buy) | +16,500 | 16,500 | ||
| 2024-05-15 | Hopfner Robert Lorne Director | Grant or award · Option (Right to Buy) | +16,500 | 16,500 | ||
| 2024-05-15 | Chung Wendy Director | Grant or award · Option (Right to Buy) | +16,500 | 16,500 | ||
| 2024-02-15 | Uden Stephen Chief Executive Officer | Grant or award · Option (Right to Buy) | +216,000 | 216,000 | ||
| 2024-02-15 | MACKAY MARTIN Executive Chairman | Grant or award · Option (Right to Buy) | +216,000 | 216,000 | ||
| 2024-02-15 | Lieber Jonathan I Chief Financial Officer | Grant or award · Option (Right to Buy) | +120,000 | 120,000 | ||
| 2024-02-15 | Ryder Steven Chief Medical Officer | Grant or award · Option (Right to Buy) | +120,000 | 120,000 | ||
| 2024-01-02 | PARMAR KUSH Director | Grant or award · Option (Right to Buy) | +27,118 | $1.77 | $48K | 27,118 |
| 2024-01-02 | HUNT RONALD Director | Grant or award · Option (Right to Buy) | +29,096 | $1.77 | $51K | 29,096 |
| 2023-05-17 | PARMAR KUSH Director | Grant or award · Option (Right to Buy) | +15,490 | 15,490 |
Page 5 of 11 · 216 trades